Simplify Your Workflow

Recommended dosing ratio1* for two FDA⁠-⁠approved products, neostigmine methylsulfate and glycopyrrolate, in one prefilled syringe

Prevduo (neostigmine methylsulfate and glycopyrrolate) Injection packaging and syringe tray
*

3 mg/3 mL (1 mg/mL) of neostigmine methylsulfate and 0.6⁠ mg/3 mL (0.2 mg/mL) of glycopyrrolate.2

PREVDUO® is an alternative to your compounded neostigmine methylsulfate and glycopyrrolate prefilled syringes and/or any 503B or FDA-approved neostigmine methylsulfate or glycopyrrolate prefilled syringes and is not intended to replace other reversal neuromuscular blocking agents (NMBAs). Please refer to the Prescribing Information for labeled indication.

To learn more about PREVDUO®, contact your Endo representative.

Prevduo (neostigmine methylsulfate and glycopyrrolate) Injection packaging and syringe tray

First and only FDA-approved neostigmine methylsulfate and glycopyrrolate combination product available in the US3

  • Two-year shelf life4† may offer enhanced inventory management
  • Does not require compounding, diluting, mixing, or transferring, which may reduce waste5
  • Aligns with medication strategies of ASHP Guidelines on Preventing Medication Errors in Hospitals5
  • Compatible with automated dispensing machine system
When stored at the recommended storage condition of 20°C to 25°C (68°F to 77°F), protected from light. Store in carton until time of use.2

Recommended dosing ratio,1 simplified

When used for reversal of nondepolarizing neuromuscular blocking agents (NMBAs), the recommended dose of glycopyrrolate injection is 0.2 mg for each 1.0 mg of neostigmine methylsulfate, as stated in the FDA-approved glycopyrrolate prescribing information.6 PREVDUO® delivers the recommended dosing ratio of neostigmine methylsulfate and glycopyrrolate in one prefilled syringe.

In a survey of anesthesiologists7‡:

In a survey of anesthesiologists, the standard dosing ratio is used in 83% of NMBA reversal cases and up to 70% of anesthesiologists have reported combining neostigmine methylsulfate and glycopyrrolate into one syringeIn a survey of anesthesiologists, the standard dosing ratio is used in 83% of NMBA reversal cases and up to 70% of anesthesiologists have reported combining neostigmine methylsulfate and glycopyrrolate into one syringe
Results of an online survey from January 2023 completed by US anesthesiologists who have at least 5 anesthesiology reversal cases in an average week and who use neostigmine methylsulfate and glycopyrrolate in at least 15% of those cases (N=112).
§When anesthesiologists or certified registered nurse anesthetists (CRNAs) were asked what ratio is usually used to prepare neostigmine methylsulfate and glycopyrrolate in the operating room (N=112).
Among those who have received standard vials for both neostigmine methylsulfate and glycopyrrolate and were asked how they usually prepare the medication for administration, 49% of respondents reported usually using 1 syringe, 21% reported sometimes using 1 syringe, and 30% reported usually using 2 individual syringes (N=91).

PREVDUO® product dimensions

Prevduo outer carton, inner tray, and prefilled syringePrevduo outer carton, inner tray, and prefilled syringe
Product NameNDCNeostigmine
Methylsulfate
Concentration
Glycopyrrolate ConcentrationPack SizeOrder Entry Number
PREVDUO®
(neostigmine
methylsulfate and
glycopyrrolate)
Injection
42023-269-053 mg/3 mL
(1 mg/mL)
0.6 mg/3 mL
(0.2 mg/mL)
5 x 3 mL
single-dose
prefilled
syringes
Cencora10280291
Cardinal5849005
McKesson2819167
M&D281584
Henry Schein1438760
McKesson Medical-Surgical1232614
M&D=Morris & Dickson; NDC=National Drug Code.